Pharma, HealthCare & MedTech

The healthcare market is more than ever driven by health economics and patient empowerment: we know the industry, its specific challenges and we prepare our clients with the right strategy.


The convergence of breakthrough scientific innovation, digital innovation and new business models are reshaping the life sciences space. Consumers’ behavior is evolving, non-traditional healthcare players are disrupting the market. Sustainable healthcare companies should put a greater focus on evidence-based therapies. The reimbursement of technologies becomes increasingly more stringent and the demands on “Innovators” become stricter. Confronted with time-consuming development and licensing processes, ever-changing legal requirements as well as immense cost pressure, healthcare companies nowadays face greater hurdles than in the past.

Multinational healthcare companies rely more and more on acquisitions, licensing and alliances. Digital transformation plays a bigger role in the sector – especially for healthcare providers.

goetzpartners supports healthcare companies in fulfilling the altered conditions and increased regulations. With a unique combination of in-depth corporate finance and management consulting expertise, we are able to work out individual and directly efficient solutions together with our clients.

China Detox

How Western healthcare systems can slim down according to the Chinese role model


Read more

Healthcare Compass Seminar

goetzpartners securities organizes the regular Healthcare Compass Seminar in London. Each event in the series explores a particular issue in the healthcare sector, bringing together leading experts, innovators, healthcare decision makers and government and private-sector advisers. Recent topics have included:

  • Early diagnosis and treatment of cancer: future outlook?
  • How can the growing cost of cancer treatment be funded, and what is the impact for the industry?
  • What can be learned from developed economies such as China to establish new, more sustainable payment models?

EUSA Pharma

Hope for children with brain tumors – Mediation during the sale of the rights of drug developer Apeiron to the EUSA Pharma marketing company 


More on this project


We have accompanied numerous healthcare-relevant transactions. With over 200 international sell-side and buy-side transactions totaling in excess of 15 billion euros in the last ten years alone, goetzpartners is one of the most successful mid-market M&A firms. This success is founded on our sector expertise and excellent process management, valued by financial investors and corporate clients alike.



goetzpartners opened the doors of the international investors’ scene for us. A small family-owned business is going to be the largest Russian producer of generics. Before starting our cooperation with goetzpartners, we knew little of this potential.

Vladimir Foteev
Medisorb Group


 Ulrich Kinzel

Ulrich Kinzel Managing Director
Corporate Finance